Last $58.58 USD
Change Today +0.61 / 1.05%
Volume 10.3M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 4:15 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$58.82
Previous Close
$57.97
Day High
$59.28
Day Low
$58.14
52 Week High
05/1/14 - $59.84
52 Week Low
11/1/13 - $44.62
Market Cap
171.2B
Average Volume 10 Days
7.5M
EPS TTM
$3.49
Shares Outstanding
2.9B
EX-Date
09/11/14
P/E TM
16.8x
Dividend
$1.76
Dividend Yield
2.99%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

Merck & Co. Inc. Layoff 600 Montgomery County Jobs

Merck & Co. Inc. is laying off 600 Montgomery County-based workers by the end of August. The jobs are being cut at the company's North Wales and Lansdale offices. The WARN (Worker Adjustment and Retraining Notification) Act requires employers to provide states with notice 60 days in advance of plant closings and large layoffs. A Merck spokeswoman told the layoffs involve primarily sales representatives. The layoff are part of the company's previously announced plans to cut 8,500 positions by the end of 2015, which represents about 20% of Merck's total workforce. Those layoffs are expected to help Merck - which like many Big Pharma companies is struggling with patent expirations and the absence of new blockbuster drugs to propel revenues - cuts expenses by $2.5 billion by the end of 2015.

Merck Initiates Phase 3 Study of Letermovir

Merck announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. In the study, letermovir will be administered once daily, either as an oral tablet or IV formulation, for 14 weeks after transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. The primary outcome measure of the study will be the percentage of participants with clinically-significant CMV infection through 24 weeks after transplant who were administered letermovir compared to placebo.

Merck & Co. Inc. Declares Fourth Quarter Dividend, Payable on October 7, 2014

Merck & Co. Inc. announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the company's common stock for the fourth quarter of 2014. Payment will be made on October 7, 2014, to stockholders of record at the close of business on September 15, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $58.58 USD +0.61

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.02 USD -1.51
Bayer AG €99.35 EUR +0.04
GlaxoSmithKline PLC 1,419 GBp +4.50
L'Oreal SA €128.25 EUR +0.60
Sanofi €76.82 EUR +0.49
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 38.2x
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow 37.5x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.